在心血管疾病的二次预防中,添加ezetimibe 添加到他类药物有没有益处?
Vinay Reddy1, James Allison1, Anne Mounsey1
1Department of Family Medicine, University of North Carolina, Chapel Hill.
The Journal of family practice
|June 20, 2023
概括
与他类药物结合使用的埃泽蒂米布可以减少心血管疾病患者的主要不良心血管事件 (MACE). 然而,与单独使用他类药物治疗相比,这种组合不会影响整体死亡率.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心血管疾病 (CVD) 仍然是全球主要的死亡原因.
- 类药物是心血管疾病管理的基石,但常常存在残留风险.
- 埃泽胺提供了替代性或辅助性降脂机制.
研究的目的:
- 评估以泽提米布与心血管疾病治疗的他类药物结合的疗效和安全性.
- 为了比较中度强度的他类药物加Ezetimibe与单独的高强度他类药物在动脉样硬化心血管疾病 (ASCVD) 的有效性.
主要方法:
- 随机对照试验 (RCT) 的元分析,包括对ezetimibe加他与单独他的大型RCT.
- 在ASCVD患者中,一个单独的RCT比较了ezetimibe与中度强度的罗斯瓦斯塔丁 (10毫克) 与单独的高强度罗斯瓦斯塔丁 (20毫克).
主要成果:
- 与单独使用他类药物相比,Ezetimibe与他类药物在已知心血管疾病患者中显著降低了主要不良心血管事件 (MACE),而不是单独使用他类药物 (SOR,A).
- 两组之间在全因或心血管死亡率上没有发现显著差异.
- 在ASCVD患者中,以泽提米布与中等强度罗斯瓦斯塔丁一起对心血管死亡,重大事件和中风进行治疗,与单独的高强度罗斯瓦斯塔丁相比,效果非劣,耐受性更好 (SOR,B).
结论:
- 除了他类药物治疗外,ezetimibe在患有已确定的心血管疾病的患者中有效降低MACE.
- 组合疗法不会增加死亡率,但提供了替代治疗策略,特别是当高强度他类药物不能耐受或不足时.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
713
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
713
01:26Atherosclerosis III: Management
15
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
15
01:26Coronary Artery Disease IV: Preventive Measures
25
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
25
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
42
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
42
01:27Coronary Artery Disease V: Interprofessional Care
11
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
11
01:26Angina IV: Management
11
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
11